Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | +0.56% | +1.43% | -28.64% |
04-26 | Exagen Inc. Announces Changes in Board of Directors | CI |
03-18 | Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-28.64% | 24.51M | C+ | ||
-14.56% | 84.68B | B- | ||
+14.96% | 81.12B | C+ | ||
+10.49% | 29.59B | C+ | ||
-8.91% | 16.73B | B | ||
-1.39% | 16.36B | A- | ||
-31.58% | 11.77B | - | - | |
+1.82% | 11.72B | A- | ||
+31.13% | 11.71B | B- | ||
-0.47% | 11.66B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- XGN Stock
- Ratings Exagen Inc.